Moonwalk Biosciences closed an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures….
BrainChild Bio raised a $116 million Series A to fund BCB-276, a B7-H3-directed autologous CAR-T therapy administered into cerebrospinal fluid, through the pivotal-intent Phase II ILLUMINATE study in newly diagnosed diffuse intrinsic pontine glioma….
HUTCHMED granted a GSK subsidiary exclusive rights outside Greater China to HMPL-A830, a preclinical antibody-targeted therapy conjugate that links an anti-EGFR antibody with a KRAS-inhibitor payload. HUTCHMED is eligible for $110 million upfront at…
Superluminal Medicines closed an oversubscribed $60 million Series B led by BVF Partners, with new participation from Deep Track Capital and Perceptive Advisors and follow-on support from RA Capital, Insight Partners, NVIDIA, Catalio, Eli…
Typewriter Therapeutics emerged from stealth with a $56 million Series A led by AN Venture Partners and RA Capital Management. The Cambridge-Tokyo startup is developing a two-component, lipid-nanoparticle-delivered RNA system intended to insert full…
Medicus Pharma licensed exclusive worldwide rights to Pfizer’s early clinical-stage CD228-targeted antibody-drug conjugate, CD228V/PF-08046031, for human disease. Medicus paid $12 million upfront, owes $15 million on the first anniversary, received $2 million in restricted…
Roche licensed exclusive global rights to Simcere Zaiming’s SIM0660, a CD79axCD19xCD3 trispecific T-cell engager intended for B-cell malignancies and autoimmune diseases. Simcere will receive $75 million upfront, up to $1.455 billion in development, regulatory…
Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, including an undisclosed upfront payment and contingent milestones. Merida is developing engineered biologics intended to remove disease-causing autoantibodies selectively while…
Genentech licensed DualityBio’s DUPAC antibody-drug conjugate platform in a deal worth $45 million upfront and more than $1 billion in potential milestones, gaining rights to a novel-payload ADC technology still in early, DualityBio-led preclinical-to-Phase…
ProFound Therapeutics received a Gates Foundation funding commitment of up to $35 million, including $20 million initially, to identify biomarkers, drug targets and potential protein therapeutics for preeclampsia and eclampsia. The program will combine…
